Abstract: Methods for producing an anti-tumor effect in a subject suffering from a cancer or a tumor are disclosed. The methods comprise administering to the patient a Vascular Disrupting Agent (VDA) that a combretastatin agent and one or more antibodies selected from the group consisting of: a CTLA-4 antibody, a PD-1 antibody, a PD-L1 antibody, and a PD-L2 antibody in amounts effective therefor. Examples of combretastatin include CA 1 P, CA4P, and their corresponding salts and prodrugs. The combination of the VDA and one or more of the antibodies produced a synergistic anti-tumor effect.
Abstract: This present disclosure is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin L, cathepsin K, and/or cathepsin B, will be therapeutically useful. Formula I: or a solvate or pharmaceutically acceptable salt thereof. Each of R1-R10 are independently selected from the group consisting of: hydrogen, alkoxy, halo, hydroxy, phosphate, phosphate salts, disodium phosphate, diphosphate dimer, diphosphate dimer salt, and sodium diphosphate dimer with at least one of R1-R10 is a phosphate or diphosphate dimer group.
Type:
Application
Filed:
August 12, 2016
Publication date:
January 10, 2019
Applicants:
Mateon Therapeutics, Inc., Baylor University
Inventors:
Kevin G. Pinney, Mary Lynn Trawick, Erica N. Parker, David J. Chaplin
Abstract: This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.
Type:
Grant
Filed:
August 31, 2016
Date of Patent:
January 23, 2018
Assignees:
Mateon Therapeutics, Inc., Baylor University
Inventors:
David J. Chaplin, Kishore Kumar Gaddale Devanna, Erica Parker, Kevin G. Pinney, Jiangli Song, Mary Lynn Trawick
Abstract: This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.
Type:
Grant
Filed:
October 2, 2014
Date of Patent:
October 4, 2016
Assignees:
Mateon Therapeutics, Inc., Baylor University
Inventors:
David J. Chaplin, Kishore Kumar Gaddale Devanna, Erica Parker, Kevin G. Pinney, Jiangli Song, Mary L. Trawick